Efficacy and safety of immunization for pre- and post- liver transplant children

Kano, Hiroki; Mizuta, Koichi; Sakakihara, Yoichi; Kato, Hitoshi; Miki, Yuko; Shibuya, Noriko; Saito, Mineo; Narita, Masami; Kawarasaki, Hideo; Igarashi, Takashi; Hashizume, Kohei; Iwata, Tadahisa

doi:10.1097/00007890-200208270-00020

Cited by 116 publications

(145 citation statements)

References 18 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…The rates of protective antibodies in our patients are significantly lower than the other studies; Balloni et al found rates of 86.2% for diphtheria and 100% for tetanus in their study (12). Also Kano et al found the rates of seroconversion against measles, rubella, and mumps after pre-transplantation vaccination 82%, 100% and 95% respectively (13). Worns et al documented that seventy-six percent of the vaccinated patients with autoimmune liver disease (against HBV vaccine) developed anti-HBs antibody (14).…”

Section: Discussioncontrasting

confidence: 64%

Evaluation of immunity status to routine vaccination in pediatric liver transplant candidates

Dehghani

Shakiba

Ziaeyan³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: Generally, prevention of infections by vaccination is the least invasive and most cost-effective approach to reduce the incidence of infections and the morbidity and mortality in transplant recipients. Genetic diversity and different liver disease among patients contributes to variability in immune responses to vaccines and pathogens. The aim of this study was to evaluate immunity status to different vaccinated organisms in pediatric liver-transplant candidates. Materials and Methods: The vaccination charts of 90 patients who were referred to Organ Transplant Center of Shiraz University of Medical Sciences were reviewed and compare with National Immunization Program recommendation, after that 10 mL blood was drawn from these patients for serologic studies by ELISA. Results: Eighty percent of the patients had protective antibody titers for poliomyelitis, 65.6% for rubella, 62.3% for diphtheria, 60% for tetanus, 57.7% for pertussis, 55.5% for measles, 42.2% for hepatitis B and 36.7% for mumps. Conclusion: Overall seroconversion rates were not satisfactory for many infections that may be due to lower rate of vaccination or even the underlying liver disease that interfere with optimal immunogenecity of vaccination. Therefore, vaccination charts should be periodically reviewed and updated, also repeated measurements of serum antibodies and appropriate revaccination if titers decline is recommended to prevent the vaccine-preventable disease in liver transplant candidates after transplant.

show abstract

Section: Discussioncontrasting

confidence: 64%

Evaluation of immunity status to routine vaccination in pediatric liver transplant candidates

Dehghani

Shakiba

Ziaeyan³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The following provides further support for the safety of MV-Edm as a viral agent: (1) liver toxicity was not observed in CD46-positive mice and squirrel monkeys treated systemically with MV-Edm (S. J. Russell, personal communication); (2) the attenuated Edmonston vaccine strain has successfully been used for vaccination with an excellent safety profile; (3) reports of wild-type measles virus-induced hepatic damage are extremely rare or have failed to show the intrahepatic presence of the measles virus 55,56 ; and (4) posttransplant measles vaccination of patients who have undergone liver transplantation does not result in significant complications and is considered safe. 57,58 The observation that CD46 expression is increased in cirrhosis, though still 3 times lower than in HCC, indicates clinical phase I toxicity studies are necessary. 43,52 In addition, our previous data showed that intraperitoneal treatment of Ifnar ™ -CD46Ge transgenic mice with MV-GFP did not result in significant transgene expression, despite the presence of MV-Edm RNA in liver tissue.…”

Section: Discussionmentioning

confidence: 99%

Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Seroconversion rates were higher in patients who had received measles vaccine before transplant (85%) as compared to children immunized only after transplantation (41%). Similarly, sustained immunity was observed in 64% of the patients previously vaccinated in comparison to 29% of the patients who were vaccinated only after transplantation 54,66,84 .…”

Section: Use Of Measles Vaccine In Special Circumstancesmentioning

confidence: 83%

Epidemiology of neglected tropical diseases in transplant recipients: review of the literature and experience of a Brazilian HSCT center

Machado

Martins

Colturato

et al. 2009

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYThe rising success rate of solid organ (SOT) and haematopoietic stem cell transplantation (HSCT) and modern immunosuppression make transplants the first therapeutic option for many diseases affecting a considerable number of people worldwide. Consequently, developing countries have also grown their transplant programs and have started to face the impact of neglected tropical diseases (NTDs) in transplant recipients. We reviewed the literature data on the epidemiology of NTDs with greatest disease burden, which have affected transplant recipients in developing countries or may represent a threat to transplant recipients living in other regions. Tuberculosis, Leprosy, Chagas disease, Malaria, Leishmaniasis, Dengue, Yellow fever and Measles are the topics included in this review. In addition, we retrospectively revised the experience concerning the management of NTDs at the HSCT program of Amaral Carvalho Foundation, a public transplant program of the state of São Paulo, Brazil.

show abstract

Efficacy and safety of immunization for pre- and post- liver transplant children

Abstract: Although 12 of 58 patients (21%) had an infection, pretransplantation immunization was effective to prevent serious illness, especially for the 6 months after transplantation. Posttransplantation live-vaccine administration under immunosuppressive conditions is effective and safe.

Cited by 116 publications

References 18 publications

Evaluation of immunity status to routine vaccination in pediatric liver transplant candidates

Evaluation of immunity status to routine vaccination in pediatric liver transplant candidates

Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

Epidemiology of neglected tropical diseases in transplant recipients: review of the literature and experience of a Brazilian HSCT center

Contact Info

Product

Resources

About